Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer
- Submitting institution
-
King's College London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 128352121
- Type
- D - Journal article
- DOI
-
10.2967/jnumed.118.224170
- Title of journal
- Journal of Nuclear Medicine
- Article number
- -
- First page
- 1213
- Volume
- 60
- Issue
- 9
- ISSN
- 0161-5505
- Open access status
- Compliant
- Month of publication
- February
- Year of publication
- 2019
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
9
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Immunotherapeutics show outstanding clinical benefit in cancers previously associated with dismal prognoses. However, selection for treatment depends on biopsy measurement of tumour PDL1 expression which may undersample; or be impossible for all metastases or longitudinal assessment. This first-in-man study of a PDL1 SPECT imaging agent, a collaboration with Shanghai University Hospital (zhaojinhua1963@126.com) and NanoMab Technology Ltd (HHTing@nano-mab.com), confirmed safety and efficacy of the tracer in non-invasive measurement of PDL1 expression in lung cancer. Our mechanistic study of lung cancer and melanoma is now recruiting (PECan trial: NCT04436406) and our Phase-2 study has been submitted for regulatory approval (PELICAN trial: EudraCT-No.2020-002809-26)
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
